Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Decroo

Showing results (11-20 of 138) with videos related to

Pageof 14
Sort By:
International Health|June 23, 2019
Temporary disengagement and re-engagement in human immunodeficiency virus care in a rural county serving pastoralist communities in Kenya: a retrospective cohort studyPaul Yonga, Stephen Kalya, Lutgarde Lynen, et al.
AIDS Research and Therapy|January 7, 2024
Effect of dolutegravir-based versus efavirenz-based antiretroviral therapy on excessive weight gain in adult treatment-naïve HIV patients at Matsanjeni health center, Eswatini: a retrospective cohort studyDidier M Mukuna, Tom Decroo, Clara M Nyapokoto
International Health|February 27, 2019
Effect of reliance on Xpert MTB/RIF on time to treatment and multidrug-resistant tuberculosis treatment outcomes in Tanzania: a retrospective cohort studyEdson Mollel, Isack Lekule, Lutgarde Lynen, et al.
Plos One|December 21, 2018
Characteristics and early clinical outcomes of key populations attending comprehensive community-based HIV care: Experiences from Nasarawa State, NigeriaOlujuwon Ibiloye, Tom Decroo, Nathaniel Eyona, et al.
Revista Panamericana De Salud Publica = Pan American Journal of Public Health|October 19, 2016
Trends in tuberculosis notification and treatment outcomes in prisons: a country-wide assessment in El Salvador from 2009-2014Gilberto Ayala, Julio Garay, Miguel Aragon, et al.
BMJ Global Health|January 23, 2025
Pretreatment attrition after rifampicin-resistant tuberculosis diagnosis with Xpert MTB/RIF or ultra in high TB burden countries: a systematic review and meta-analysisChristelle Geneviève Jouego, Tom Decroo, Palmer Masumbe Netongo, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 2020
Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?Sabira Tahseen, Armand Van Deun, Bouke C de Jong, et al.
BMC Infectious Diseases|October 13, 2017
Rational use of Xpert testing in patients with presumptive TB: clinicians should be encouraged to use the test-treat thresholdTom Decroo, Aquiles R Henríquez-Trujillo, Anja De Weggheleire, et al.
AIDS Research and Treatment|May 12, 2012
Are Expert Patients an Untapped Resource for ART Provision in Sub-Saharan Africa?Tom Decroo, Wim Van Damme, Guy Kegels, et al.
Journal of the International AIDS Society|March 21, 2019
ART adherence clubs in the Western Cape of South Africa: what does the sustainability framework tell us? A scoping literature reviewKornelia Flämig, Tom Decroo, Bart van den Borne, et al.
Pageof 14

Showing results (11-20 of 138) with videos related to

Sort By:
Pageof 14
International Health|June 23, 2019
Temporary disengagement and re-engagement in human immunodeficiency virus care in a rural county serving pastoralist communities in Kenya: a retrospective cohort studyPaul Yonga, Stephen Kalya, Lutgarde Lynen, et al.
AIDS Research and Therapy|January 7, 2024
Effect of dolutegravir-based versus efavirenz-based antiretroviral therapy on excessive weight gain in adult treatment-naïve HIV patients at Matsanjeni health center, Eswatini: a retrospective cohort studyDidier M Mukuna, Tom Decroo, Clara M Nyapokoto
International Health|February 27, 2019
Effect of reliance on Xpert MTB/RIF on time to treatment and multidrug-resistant tuberculosis treatment outcomes in Tanzania: a retrospective cohort studyEdson Mollel, Isack Lekule, Lutgarde Lynen, et al.
Plos One|December 21, 2018
Characteristics and early clinical outcomes of key populations attending comprehensive community-based HIV care: Experiences from Nasarawa State, NigeriaOlujuwon Ibiloye, Tom Decroo, Nathaniel Eyona, et al.
Revista Panamericana De Salud Publica = Pan American Journal of Public Health|October 19, 2016
Trends in tuberculosis notification and treatment outcomes in prisons: a country-wide assessment in El Salvador from 2009-2014Gilberto Ayala, Julio Garay, Miguel Aragon, et al.
BMJ Global Health|January 23, 2025
Pretreatment attrition after rifampicin-resistant tuberculosis diagnosis with Xpert MTB/RIF or ultra in high TB burden countries: a systematic review and meta-analysisChristelle Geneviève Jouego, Tom Decroo, Palmer Masumbe Netongo, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 2020
Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?Sabira Tahseen, Armand Van Deun, Bouke C de Jong, et al.
BMC Infectious Diseases|October 13, 2017
Rational use of Xpert testing in patients with presumptive TB: clinicians should be encouraged to use the test-treat thresholdTom Decroo, Aquiles R Henríquez-Trujillo, Anja De Weggheleire, et al.
AIDS Research and Treatment|May 12, 2012
Are Expert Patients an Untapped Resource for ART Provision in Sub-Saharan Africa?Tom Decroo, Wim Van Damme, Guy Kegels, et al.
Journal of the International AIDS Society|March 21, 2019
ART adherence clubs in the Western Cape of South Africa: what does the sustainability framework tell us? A scoping literature reviewKornelia Flämig, Tom Decroo, Bart van den Borne, et al.
Pageof 14